首页 | 本学科首页   官方微博 | 高级检索  
检索        

两种方案治疗晚期非小细胞肺癌的疗效观察
引用本文:汪芳林.两种方案治疗晚期非小细胞肺癌的疗效观察[J].海南医学院学报,2009,15(8):867-869,872.
作者姓名:汪芳林
作者单位:合肥市第一人民医院肿瘤内科,安徽合肥,230061
基金项目:海南医学院科研基金资助学报项目 
摘    要:目的:评价吉西他滨联合顺铂(GP)、多西紫杉醇联合顺铂(DP)2种化疗方案治疗晚期非小细胞肺癌患者的近期疗效和毒性。方法:选择68例ECOG计分≤2、生存期超过3个月、白细胞计数〉4.0×10^9/L、肝肾功能正常、无活动性感染征象的Ⅲ期或Ⅳ期非小细胞肺癌患者分为两组,34例给予GP方案泽菲(G)1000mg/m^2,静脉滴注,D1、8;顺铂(P)80mg/m^2,静脉滴注,D1-5,34例给予DP方案多西紫杉醇(D)75rng/m^2,静脉滴注,D1,顺铂(P)80mg/m^2,静脉滴注,D1-5],比较2种化疗方案的疗效和不良反应。结果:GP组和DP组的客观有效率分别为41.2%和47.1%,两组间差异无统计学意义(P〉0.05)。两组3/4度不良反应发生率较总的不良反应率明显下降,GP组血小板下降发生率明显高于DP组(P〈0.05),脱发发生率明显低于DP组(P〈0.05);DP组3/4度不良反应中局部反应、脱发、便秘和周围神经炎的发生率高于GP组(P〈0.05),其它3/4度不良反应差异无统计学意义(P〉0.05)。GP组和DP组的1年生存率分别为41.2%、44.1%,疾病进展中位数时间分别为5.8、6.1个月,差异无统计学意义(P〉0.05)。结论:新的含铂二药联合方案GP、DP高效、安全,可作为非小细胞肺癌一线标准方案的良好选择。

关 键 词:非小细胞肺癌  化学疗法  吉西他滨  多西紫杉醇  顺铂

Evaluation of two kinds of chemotherapy on advanced non-small-cell cancer
WANG Fang-lin.Evaluation of two kinds of chemotherapy on advanced non-small-cell cancer[J].Journal of Hainan Medical College,2009,15(8):867-869,872.
Authors:WANG Fang-lin
Institution:WANG Fang-lin (Department of Tomour, First People's Hospital of Hefei Hefei 230011, China)
Abstract:Objective:To evaluate the efficacy and adverse reactions of gemcitabine plus cisplatin ( GP ) and docetaxel plus cisplatin ( DP ) in the treatment of advanced non-small-cell lung cancer ( NSCLC ). Methods:Sixty-eight patients with NSCLC selected by certain criteria were divided into 2 groups (group A and B),each group had 34 cases,the inclusive criteria included:ECOG ≤ 2 points,survival time more than three months,WBC counts>4.0×109/ L ,normal liver and renal function,no symptoms and signs of active infection,III or Ⅳ stage of pathology. Patients in group A were treated with gemcitabine plus cisplatin (GP) gemcitabinei(G) 1 000 mg/m2,intravenous infusion,D1,8; cisplatin (P) 80 mg/m2,intravenous infusion,D1-5] and patients in group B were treated with docetaxel plus cisplatin (DP) docetaxel (D) 75mg/m2,intravenous infusion,D1,cisplatin (P) 80mg/m2,intravenous infusion,D1-5]. The efficacy and adverse reactions were observed and studied. Results:The objective overall response rates of group A and B were 41.2% and 47.1% respectively,the difference between group A and B was not significant(P>0.05). The Ⅲ~Ⅳ degree adverse reactions were less than total adverse reactions in the two groups,the incidence of thrombocytopenia in group A was significantly higher than that in group B (P<0.05),the incidence of hair loss in group A was significantly lower than that in group B (P<0.05); 3 / 4 degree of adverse reactions including local reactions,hair loss,constipation,and peripheral neuritis in group B were significantly higher than that in group A (P<0.05),the other 3 / 4 degree of adverse reactions were no significant difference between the group A and B(P>0.05). 1-year survival rate in group A and B was 41.2% and 44.1% respectively,the median time to disease progression in group A and B was 5.8 months and 6.1 months respectively. Conclusion:New platinum-based combining chemotherapy,such as GP and DP,has higher efficacy and more safety; it could be a new and better chemotherapy of advanced NSCLC.
Keywords:Non-small-cell lung cancer  Chemotherapy  Gemcitabine  Docetaxel  Cisplatin
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号